Global Limbal Stem Cells Deficiency Market

The Global Limbal Stem Cells Deficiency Market Size was worth around USD 209.5 Million in 2024 and is predicted to grow to around USD 532.0 Million by 2035 with a compound annual growth rate (CAGR) of 8.84% from 2025 and 2035. The market for limbal stem cells deficiency has a number of opportunities to grow due to the expanding stem cell and regenerative medicine platforms, increased funding for ocular rare disease research, and development of gene therapy & iPSC based solutions.

Market Overview

The global industry for limbal stem cells deficiency focused on diagnosing and treating a rare, blinding eye condition caused by damage to corneal stem cells, leading to severe pain and vision loss from corneal scarring. Regenerative, cell-based therapies such as cultured limbal epithelial transplantation (CLET) and other surgical innovations are driving the limbal stem cells deficiency market. Limbal stem cell deficiency (LSCD) is a condition caused by the loss or dysfunction of stem cells at the corneal limbus, preventing proper corneal surface regeneration.

Innovation and market expansion are anticipated as a result of major players' growing R&D expenditures and the expanding partnerships. For instance, in September 2025, Mytos advances automated iPSC manufacturing through a strategic partnership with StemSight, Rinri Therapeutics, and Novadip.